Biopharma’s Quantum Leap

January 8, 2024

In the ever-evolving landscape of industries transformed by artificial intelligence, one might wonder if there are limits to where AI can make an impact. Enter drug discovery – an arena traditionally lacking the big data needed for conventional machine learning approaches. But here at SandboxAQ, we're rewriting the rules with our groundbreaking AI-powered quantum simulation technologies, which we call AQ.

Our mission is clear: to revolutionize drug development by leveraging AI-powered quantum simulations that not only de-risk drug portfolios but also optimize compounds prior to entering preclinical and clinical phases. Our new AQBioSim division has pioneered techniques that bring AI to the forefront of drug discovery, even in cases where data is scarce. By harnessing the power of our proprietary simulations, we're able to train models at lightning speed to provide swift and efficient solutions. Furthermore, our approach extends to performing optimizations across our simulations, creating a comprehensive toolkit for drug development.

What sets us apart is our ability to concurrently optimize for multiple critical factors, such as toxicity and binding affinities. For an industry that has traditionally required a decade or more and billions of dollars to develop a single new compound – with little guarantee of success – AQ-powered drug discovery is nothing short of game-changing.

We're honored to have garnered recognition from esteemed researchers like Dr. Stanley B. Prusiner, Nobel Laureate and Director of the Institute for Neurodegenerative Diseases at the University of California, San Francisco (UCSF). Dr. Prusiner noted that SandboxAQ's novel molecular simulation technology has for the first time “enabled the application of rational and structure-based drug design methods to the challenging systems we encounter daily in drug discovery.” Dr. Prusiner added that this technology has proven particularly impactful in tackling neurodegenerative diseases, such as Alzheimer's and Parkinson's, and holds promise for various other indications. "We are confident that this platform, including AQ-FEP, will continue to help us revolutionize the way we develop drugs across our other disease focus areas."

Through our partnership with UCSF, we've managed to significantly shorten discovery timelines and expedite lead optimization. Our proprietary Absolute Free Energy Perturbation (AQ-FEP) software has enabled UCSF researchers to swiftly and accurately generate thousands of predictions. In a matter of months, this approach has led to the identification and optimization of promising new compounds, enhancing the likelihood of their success in clinical trials.

Behind the scenes, our collaborative efforts encompass a diverse team of physicists, biologists, and computational and medicinal chemists, and a world-class advisory board. Together, we've mastered the art of scaling up quantum chemical simulations using cutting-edge classical hardware. By fusing these advanced tools with AI capabilities, we offer a comprehensive suite of solutions that propel drug discovery into the fast lane.

These solutions are particularly revolutionary for instances where the target molecule is complex and challenging to simulate, for example, neurodegenerative diseases. Unlike conventional receptors, these proteins are structurally complex, requiring binding and subsequent analysis. This is the niche we're pioneering, and it's the solution our clients seek.

Leveraging AQ, we're propelling drug discovery into a new era with a holistic approach that is not only reducing costs and time but, crucially, mitigating risks associated with molecules before they even reach the clinic. 

If you would like to explore how our AI-powered quantum simulations are revolutionizing the field and setting new standards for success in biopharma, reach out today.

No items found.